Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Technical Presentation (April 2020)

24 slides from Avadel Pharmaceuticals's technical presentation, Apr 27, 2020

  1. Slide 1: REST-ON Pivotal Phase 3 Trial: Topline Results

    REST - ON Pivotal Phase 3 Trial: Topline Results April 27, 2020

  2. Slide 2: Safe Harbor

    Safe Harbor 2 This presentation may include forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expression

  3. Slide 3: Gregory Divis, Chief Executive Officer

    Gregory Divis Chief Executive Officer 3

  4. Slide 4: REST-ON Phase 3 Study – Positive Topline Results

    4 REST - ON Phase 3 Study – Positive Topline Results Once - nightly FT218 demonstrated highly statistically significant (p<0.001), clinically meaningful improvement compared to placebo at all three doses for all three co - primary endpoints Once - nightly FT218 was generally well - tolerated at the

  5. Slide 5: Characteristics of Narcolepsy – Serious Disease with Large Unmet Need

    Characteristics of Narcolepsy – Serious Disease with Large Unmet Need 5 Under - diagnosed, chronic, disabling neurological disease Characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nocturnal sleep, hypnagogic hallucinations, and sleep paralysis Twice - nightly sodium oxybate

  6. Slide 6: Leveraging Our Proprietary Micropump Technology – Delivering Sodium Oxybate Once Nightly

    Leveraging Our Proprietary Micropump™ Technology – Delivering Sodium Oxybate Once Nightly • Technology contains thousands of micro particles – Each is a miniature delivery system • Microparticulate design can be adapted to each drug’s specific challenges – Modify coatings / thickness Delayed deliver

  7. Slide 7: Initial PK Studies Indicated Potential Advantages of Once-Nightly FT218

    0 20 40 60 80 100 0 2 4 6 8 10 Time (h) GHB Concentration (ug/mL) Mean and Standard Error FT218, n=26 Twice - nightly sodium oxybate, n=27 Mean PK Profiles (6 g) Initial Pharmacokinetic (PK) Studies Indicated Potential Advantages of Once - Nightly FT218 The Comparison to 2X Nightly The Results 7 Sin

  8. Slide 8: Jordan Dubow, MD, Chief Medical Officer

    Jordan Dubow, MD Chief Medical Officer 8

  9. Slide 9: Positive Topline Phase 3 Results Across All Doses For All Co-Primary Endpoints

    Positive Topline Phase 3 Results Across All Doses Studied For All Co - Primary Endpoints 9 Once - Nightly FT218 at 9 g demonstrated a high degree of statistical significance, compared to placebo, for each of the three co - primary endpoints: • Maintenance of Wakefulness Test (MWT) (p<0.001) • Clinic

  10. Slide 10: REST-ON Phase 3 Study Design

    3 weeks Baseline REST - ON Phase 3 Study Design 10 Placebo FT218 1 2 3 4 5 6 7 8 9 10 11 12 13 1:1 Randomization 4.5 g 6 g 7.5 g 9 g Weeks safety and efficacy assessments

  11. Slide 11: REST-ON Phase 3 Study – Key Inclusion and Exclusion Criteria

    REST - ON Phase 3 Study – Key Inclusion and Exclusion Criteria • Age: 16 and over • Documented diagnosis of narcolepsy (NT1 or NT2) as defined by the International Classification of Sleep Disorders - 3 criteria • Epworth Sleepiness Score (ESS): >10 • May be on stimulants, as long as stable for three

  12. Slide 12: REST-ON Study – Three Co-Primary Endpoints and Statistical Analysis Plan

    REST - ON Study – Three Co - Primary Endpoints and Statistical Analysis Plan Change from baseline to endpoint for FT218 compared to placebo at 9 g for: 1. Maintenance of Wakefulness Test 2. Clinical Global Impression - Improvement (% of patients “much” or “very much” improved) 3. Mean weekly cataple

  13. Slide 13: FT218 9 g was Significant on the MWT Compared to Placebo

    FT218 9 g was Significant on the MWT Compared to Placebo Change from Baseline to Week 13 for FT218 was 10.82 Change from Baseline to Week 13 for Placebo was 4.69 LS Mean difference between FT218 and Placebo was 6.13 ( p<0.001) Change From Baseline in MWT 4.69 10.82 -1 1 3 5 7 9 11 13 15 Placebo FT21

  14. Slide 14: FT218 9 g Had Significant Improvement on the CGI-I Compared to Placebo

    FT218 9 g Had Significant Improvement on the Clinical Global Impression - Improvement (CGI - I) Compared to Placebo 72.0% of patients on FT218 compared to 31.6% of patients on placebo were rated as much or very much improved at Week 13; odds ratio 5.56 (p<0.001) CGI - I - Percent Much or Very Much I

  15. Slide 15: FT218 9 g Had Significant Reduction in Mean Weekly Cataplexy Attacks

    FT218 9 g Had Significant Reduction in Mean Weekly Cataplexy Attacks Compared to Placebo 15 Change from Baseline to Week 13 for FT218 was - 11.51 Change from Baseline to Week 13 for Placebo was - 4.86 LS Mean difference between FT218 and Placebo was - 6.65 (p<0.001) Change From Baseline in Weekly Ca

  16. Slide 16: FT218 9 g was Generally Well Tolerated with Low Rates of Adverse Reactions

    FT218 (%) Placebo (%) Any Adverse Drug Reaction (ADR) 35.1 5.0 Any Serious ADR 1.3 0.0 ADR Leading To Discontinuation 3.9 0.0 FT218 9 g was Generally Well Tolerated with Low Rates of Commonly Reported Sodium Oxybate Adverse Reactions Common ADRs Nausea 1.3 1.3 Vomiting 5.2 0.0 Decreased Appetite 2.6

  17. Slide 17: FT218 7.5 g and 6 g was Significant on the MWT Compared to Placebo

    FT218 7.5 g and 6 g was Significant on the MWT Compared to Placebo 17 Change from Baseline to Week 8 for FT218 7.5 g was 9.55, compared to 3.34 for placebo LS Mean difference between FT218 7.5 g and Placebo was 6.21 (p<0.001) Change from Baseline to Week 3 for FT218 6 g was 8.08, compared to 3.1 for

  18. Slide 18: FT218 7.5 g and 6 g Had Significant Improvements on the CGI-I

    18 62.6% of patients on FT218 7.5 g compared to 22.8% of patients on placebo were rated as much or very much improved at Week 8; Odds Ratio 5.67 ( p<0.001) 40.1% of patients on FT218 6 g compared to 6.1% of patients on placebo were rated as much or very much improved at Week 3; Odds Ratio 10.29 (p<0

  19. Slide 19: FT218 7.5 g and 6 g Had Significant Reductions in Mean Weekly Cataplexy Attacks

    FT218 7.5 g and 6 g Had Significant Reductions in Mean Weekly Cataplexy Attacks Compared to Placebo 19 Change from Baseline to Week 8 for FT218 7.5 g was - 9.98, compared to - 3.71 LS Mean difference between FT218 7.5 g and Placebo was - 6.27 (p<0.001) Change from Baseline to Week 3 for FT218 6 g wa

  20. Slide 20: Q&A

    *Avadel” Q&A

  21. Slide 21: Closing Remarks

    \vAvadel” Closing Remarks

  22. Slide 22: What to Expect: Once-Nightly FT218 Next Steps

    WHAT TO EXPECT: Once - Nightly FT218 Next Steps Event Status REST - ON completion and topline data Complete Switch and Open Label Extension study In - progress Full REST - ON analysis and complete study report In - progress Pre - NDA meeting In - progress NDA completion and submission In - progress

  23. Slide 23: At a Glance: Once Nightly FT218: All the Ingredients for Success

    AT A GLANCE Once Nightly FT218: All the Ingredients for Success 23 FT218 Completed Pivotal Study ~$1.7B a differentiated product with high potential REST - ON Ph3 study, single study required for approval (SPA agreement) 17 YEARS D EMONSTRATED highly significant results across all three co - primary

  24. Slide 24: REST-ON Pivotal Phase 3 Trial: Topline Results

    24 REST - ON Pivotal Phase 3 Trial: Topline Results

Avadel Pharmaceuticals — Technical Presentation (April 2020) on 6ix